Neurology - School of Medicine Dundee

Part of the School of Dundee and NHS Tayside

Dr Jonathan O’Riordan Publications

Publications:  Peer review journals                                                       

 

Multiple Sclerosis – basic research

 

  1. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do  alpha‑blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153(4):1114 – 1116
  2. Losseff NA, Webb SW, O'Riordan J, Page R, Wang L, Barker G, Tofts P, McDonald WI, Miller DH, Thompson AJ. A new reproducible and sensitive technique to measure disease progression in multiple sclerosis: tissue destruction in the spinal cord measures by MRI: method and correlation with clinical disability. Brain 1996;119:701 – 708
  3. Giovannoni G, Heales SJR, Silver N, O'Riordan J, Miller RF, Land JM, Thompson EJ. Raised serum nitrate plus nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997;145: 77 – 81
  4. Robertson NP, O’Riordan JI, Chataway J, Kingsley DPE, Miller DH, Clayton D, Compston DAS. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997; 349: 1587 – 1590
  5. Gawne-Cain M, O’Riordan JI, Thompson AJ,Moseley I,McDonald WI and Miller DH. Multiple sclerosis lesion detection in the brain: A comparison of fast fluid attenuated inversion recovery and conventional T2 weighted dual spin echo. Neurology 1997; 49: 364 – 370
  6. O’Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The prognostic value of brain MRI in clinically isolated syndromes of the central nervous system - a 10 year follow up. Brain 1998; 121: 495 – 503
  7. O’Riordan JI, Losseff NA, Phatorus C, Thompson AJ, Moseley IF, MacManus DG, McDonald WI, Miller DH. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry 1998; 64: 353 – 357.
  8. O'Riordan JI, Gawne-Cain M, Coles A, Compston DAS, Tofts P, Miller DH. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparsion between pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Multiple Sclerosis 1998; 4: 408 – 412
  9. Gawne-Cain ML, O’Riordan JI, Coles A, Newell B, Thompson AJ, Miller DH. MRI lesion volume measurement in MS and its correlation with disability: a comparsion of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences. J Neurol Neurosurg Psychiatry 1998; 64: 197 – 20
  10. Sailer M, O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, McDonald WI, Miller DH. Long term predictive value of quantitative brain MRI in patients presenting with clinically isolated syndromes suggestive of demyelination. Neurology 1999; 52: 599 -606
  11. Brex PA, O’Riordan JI, Miszkeil KA, Moseley IF, Thompson AJ, Plant GT, Miller DH. Multisequence MRI in clinically isolated syndromes and early development of MS. Neurology 1999; 53 (6): 1184 – 1190.
  12. Giovannoni G, Silver N, O’Riordan J, Miller RF, Heales SJ, Land JM, Elliot M, Feldman M, Miller DH, Thompson EJ. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult Scler 1999; 5: 335 – 34
  13. Brex PA, Jenkins R, Fox NC, Crum WR, O’Riordan JI, Plant GT, Miller DH. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689 – 1691
  14. Brex PA, Leary SM, O’Riordan JI, Miszkiel KA, Barker GJ, Plant GT, Thompsom AJ, Miller DH. Measurement of spinal cord area in clinically isolated syndromes suggestive of MS. J Neurol Neurosurg Psychiatry 2001; 70: 544-547
  15. Brex PA, Mizkiel KA, O’Riordan JI, Plant GT, Moseley IF, Thompson AJ, Miller DH. Assessing the risk of early multiple sclerosis patients with clinically isolated syndromes: the role of follow-up MRI. J Neurol Neurosurg Psych 2001; 70:3390 – 393
  16. Parratt J, Tavendale R, Parratt D, O'Riordan J, Swingler RJ. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2001; 57: 746 (post publication peer review letter)
  17. Brex P, Ciccarelli O, Miller DH, O’Riordan JI, Sailer M, Thompson AJ. A longitudinal study of MRI abnormalities and disability from multiple sclerosis. N Eng J Med 2002; 346: 158 – 16
  18. CM Dalton, PA Brex, R Jenkins, NCC Fox, KA Miszkiel, WR Crum, JI O’Riordan, GT Plant, AJ Thompson, DH Miller. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated the development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141-147
  19. Parratt J, Donnan P, Wilson SV, O'Riordan JI, Swingler RJ, Forbes RB. Multiple sclerosis distribution in northern Sardinia: spatial cluster analysis of prevalence.
    Neurology 2003; 59(5):790
  20. Donnan P, Parratt J, Wilson S, Forbes R, O'Riordan JI, Swingler R. Multiple sclerosis in Tayside, Scotland: detection of clusters using a spatial scan statistic. Multiple sclerosis 2005; 11: 403-408
  21. Parratt J, Tavondale R, O’Riordan J, Parratt D, Swingler. Chlamydia pneumoniae specific serum immune complexes in patients with multiple sclerosis. Multiple Sclerosis 2008; Mult Scler. 2008 Apr;14(3):292-9
  22. Foley P,Reilly P,Coulson A, O’Riordan JI. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.  J R Coll Physicians Edin 2010; 40: 105-110
  23. J C Correia de Sa, L Airas, E Bartholome, N Grigoriadis, J Hillert, H Mattle, C Oreja-Guevara, J O’Riordan, F Sellebjerg, B Stankoff, K Vass, A Walczak, H Wiendl, B Kieseier. Sympto1matic therapy in multiple sclerosis – a review for a multimodal approach in clinical practice. Therapeutic Advances in Neurological Disorders 2011; 4(3): 139-168
  24. Mackenzie IS, Morant SV, Bloomfield GA, Macdonald TM, O'Riordan J. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry. 2013 Sep 19. doi: 10.1136/jnnp-2013-305450. [Epub ahead of print]

 

Multiple Sclerosis Clinical Trials – principal investigator

The European study group on Interferon Beta 1b in secondary progressive MS

  1. European Study Group on Interferon ß-1b in secondary progressive MS.  Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis.  Lancet 1998; 352: 1491 – 1497.
  2. Miller DH, Molyneux P, Barker G, MacManus D, Wagner K and the European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999; 46(6): 850 – 859.
  3. Molyneux PD, Kappos L, Polman C, Pozzilli C, Losseff NA, Thompson AJ, Miller DH and the European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123:2256-2263.
  4. Freeman J, Thompson A, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C, and the European study group on Interferon Beta 1b in secondary progressive MS. Neurology 2001; 57: 1870-1875
  5. Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dalke F, Filippi M, Ghazi M, Hahn D, MacManus D,Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K Yousry T, Miller DH,European Study Group on Interferon Beta 1b in secondary progressive MS. Neurology 2001; 57: 2191-2197
  6. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dalke F, the European study group on Interferon Beta 1b in secondary progressive MS. Final analysis of the European multicenter trial on IFNb-1b in secondary progressive MS. Neurology 2001; 57:1969-1975
  7. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dalke F, the European study group on Interferon Beta 1b in secondary progressive MS. Final analysis of the European multicenter trial on IFNb-1b in secondary progressive MS. Neurology 2001; 57:1969-1975

 

The UK MS Research Group

  1.  Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, the UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to ultiple sclerosis (CAMS study): multi centre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.

Benefit Study Group

  1.  Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkof F, Redo EW, Baur L, Dahms S, Lanius V, Pohl C, Sandbrink R; Benefit Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 Aug 4;370(9585):389-97
  2.  Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkof F, Redo EW, Baur L, Dahms S, Lanius V, Pohl C, Sandbrink R; Benefit Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 Aug 4;370(9585):389-97
  3. Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b..J Neurol. 2008 Apr;255(4):480-7.
  4. Interferon B-1b neutralising antibodies 5 years after clcinically isolated syndrome. Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Neurology. 2011 Aug 30;77(9):835-43. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317

9011 study group

  1. De Stefano N, Filippi M, Hawkins C; 9011 study group Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis..J Neurol Sci. 2008 Mar 15;266(1-2):44-50.

Rebif New Formulation Study Group

  1. Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; Rebif New Formulation Study Group. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009 Feb;15(2):219-28

 

The Sativex Spasticity Study Group

  1. A randomized , double-blind,placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®)), as add on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P; the Sativex Spasticity Study Group. Eur J Neurol. 2011 Mar 1. doi: 10.1111/j.1468-1331

TEMSO Trial Group

  1. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. N Engl J Med. 2011 Oct 6;365(14):1293-303

Devic's Neuromyelitis Optica/Acute Dessimminated Encephalomyelitis/Sarcoid

  1. Javed MA, O'Riordan JI, Murphy RP. Adrenoleukodystrophy. P J Neurol 1995; 1:8 - 11
  2. O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica J Neurol Neurosurg Psychiatry 1996; 60:382 – 387
  3. O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica J Neurol Neurosurg Psychiatry 1996; 60:382 – 387
  4. O’Riordan JI. Central nervous system white matter diseases other than multiple sclerosis. Cur Opin Neurol 1997; 10:211 - 214.
  5. O’Riordan JI, Walker M, Plant GT, Graham EM. Non communicating syringomyelia and neuromyelitis optica. J Neurol 1999; 246: 314 – 316.
  6. O’Riordan JI, Gomez-Anson B, Moseley IF, Miller DH. Long term MRI follow-up of patients with post infectious encephalomyelitis: evidence for a monophasic disease. J Neurol Sci 1999; 167: 132 – 136.
  7. CS Mathieson, D Mowle, JW Ironside, J O'Riordan. Isolated cervical intramedullary sarcoidosis--a histological surprise. British Journal of Neurosurgery 2004; 18: 632-635

 

Mysathenia gravis/Peripheral Nervous System

  1. O'Riordan J, Javed M, Doherty C, Hutchinson M. Worsening of myasthenia gravis on treatment with imipenem/cilastatin. J Neurol Neurosurg Psychiatry 1994; 57: 383
  2. O'Riordan JI, Hayes J, FitzGerald MX, Redmond J. Peripheral nerve dysfunction in adult patients with cystic fibrosis. Ir J Med Sci 1995;164(3):207 ‑ 208
  3. O’Riordan JI, Brenner R, Howard RS, Miller DH. Nephrotic syndrome developing in association with thymoma and myasthenia gravis. Eur J Neurol 1997; 4: 416 – 418.
  4. Hughes RAC, Swan A, Cornblath D, Hartung H, Bril V, Feasby T, Hahn A, Miller DH, Howard R, O’Riordan JI, Chalk C,Ben Hur T,Goldstein J,Van Orshoven M, Schmedding E, Ferguson I, Caekebeke J, Stoll G, Will R, Pollard J. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997; 349: 225 - 230
  5. O’Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 1998; 5:137 – 142
  6. O’Riordan JI, Miller DH, Mottershead JP, C Pattison, Hirsch NP, Howard RS. Thymectomy: its role in the management of myasthenia gravis. Eur J Neurol 1998; 5: 211- 216
  7. Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV and the Plasma Exchange/Sandoglobulin Guillain-Barre syndrome trial group. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome.  Ann Neurol 1998: 44: 780 - 788
  8. O' Riordan J, Swingler RJ, Malek N. Use of intravenous immunoglobulin in the Department of Neurology at Ninewells Hospital, 2008-2009: Indications for utilization and cost-effectiveness. Ann Indian Acad Neurol 2010; 13(4): 271-275
  9. Foley P, Oommen G, O’Riordan J. A woman with a cough and difficulty walking. BMJ 2010; 341:c3674

Epilepsy

  1. O'Riordan JI. Blackouts - an approach to diagnosis in general practice. Ir Med Times 1993;27:30 – 31.
  2. O'Riordan JI. Treatment of epilepsy in elderly patients. Ir Med News 1994;11:14
  3. O'Riordan JI, Hutchinson J, FitzGerald MX, Hutchinson M. Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury. J Neurol Neurosurg Psychiatry 1994;57:643-645
  4. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O’Riordan JI. A harmless high?. Lancet 2010; 376(9742): 742

Cerebrovascular Disease

  1. Kellett‑JG; O'Riordan‑J. Whither the rationale for thrombolytic agent administration? A retrospective review of traditional intuitive decision‑making using a decision analysis model. Ir J Med Sci 1993; 162(4):133- 139
  2. Kellet J, O'Riordan JI.A thrombolytic decision tree. Clinical Computing 1992; 9:157- 164
  3. O'Riordan JI, Javed M, Rawluk D, Murphy R.Cavernous haemangiomas of the central nervous system-no longer occult lesions. Ir J Med Sci 1994;163(7):324‑327
  4. O'Riordan‑JI, Javed‑M, Murphy‑R, Hutchinson‑M. Sneddon's syndrome ‑ clinical course and out‑come. Ir Med J 1995;88(2): 66 – 67
  5. Hutchinson M, O'Riordan J, Javed M, Quin E, Macerlaine D, Wilcox T, Parfrey N, Nagy‑TG; Tournier‑Lasserve‑E. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol 1995;38(5):817 – 824

Scottish Intracranial Vascular Malformation Study Collaborator

  1. Al-Shahi R, Bhattacharya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP; Scottish Intracranial Vascular Malformation Study Collaborators. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intranial Vascular Malformation Study (SIVMS). Stroke. 2003 May;34(5):1163-9. Epub 2003 Apr 17
  2. Al-Shahi R, Bhattacharya JJ, Currie DG, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP; Scottish Intracranial Vascular Malformation Study Collaborators. Scottish intracranial vascular malformation study (SIVMS): evaluation of methods, ICD-10 coding, and potential sources of bias in a prospective, population based cohort. Stroke. 2003 May;34(5):1156-62. Epub 2003 Apr 17. Erratum in: Stroke. 2003 Jun;34(6):1573.
  3. Cordonnier C, Al-Shahi Salman R, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow C; SIVMS Collaborators. Differences between intracranial vascular malformation types in the characteristics of their presenting haemorrhages: prospective, population-based study. J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):47-51. Epub 2007 May 8
  4. Wedderburn CJ, van Beijnum J, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie  V, Roberts RC, Sellar RJ, Warlow CP, Al-Shahi Salman R; SIVMS Collaborators. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study. Lancet Neurol. 2008 Mar;7(3):223-30
  5. Hon JM, Bhattacharya JJ, Counsell CE, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP, Al-Shahi Salman R; SIVMS Collaborators. The presentation and clinical course of intracranial developmental venous anomalies in adults: a systematic review and prospective, population based study. Stroke. 2009 Jun;40 (6):1980-5.
  6. Al-Shahi Salman R, Hall JM, Horne MA, Moultrie F, Josephson CB, Bhattacharya JJ, Counsell CE, Murray GD, Papanastassiou V, Ritchie V, Roberts RC, Sellar RJ, Warlow CP; Scottish Audit of Intracranial Vascular Malformations (SAIVMs) collaborators. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. 2012 Mar;11(3):217-24.

Miscellaneous/General Neurology

  1. O'Riordan JI. The therapeutics of migraine. Ir Med News 1993;39:14 - 15
  2. Dolan R, Houston G, O'Riordan J. Brown-Séquard syndrome due to noncompressive disc prolapse and spinal cord infarction. QJM. 2009 Mar;102(3):225-7.
  3. Farrugia ME, O’Riordan JI. Olfactory bulb contusion: MRI and histological correlation. Proc R Coll Physicians Edin 2001; 31: 231-233
  4. Nelson A, Aljafari A, Shah P, Eljamel MS, O’Riordan JI. Pneumocephaly following CSF examination in association with an ethmoid osteoma. J Neurol Neurosurg Psychiatry 2007; 78(10):1149-51
  5. Dolan, R, Thomas, R, O'Riordan, J. Paraneoplastic Ataxia and Dystonia secondary to a malignant fibrous histiocytoma. BMJ Case Reports 2010; doi:10.1136/bcr.05.2010.2983
  6. Anwar MS, Waddell B, O'Riordan J. Neurological improvement following reinstitution of a low phenylalanine diet after 20 years in established pnenylketonuria. BMJ Case Rep. 2013 Jul 12;2013. doi:pii: bcr2013010509

 

 

 

 

 

 

Presentations to learned societies & scientific meetings

 

  1. O'Riordan JI, Javed M, Hutchinson M, Murphy RPM. Cavernous haemangiomas of the CNS - no longer occult lesions (1993) Presented at the Irish Neurological Society
  2. Doherty C, O’Riordan J, Hutchinson M, Quinlan D. Male sexual dysfunction in multiple sclerosis (1993). Presented at the Irish Neurological Society
  3. Javed M, O’Riordan J, Murphy R. Emery Dreifus mucsular dystrophy: a family with autosomal dominant inheritance (1993). Presented at the Irish Neurological Society
  4. O’Riordan JI, Doherty C, Javed M, Hutchinson M, Quinlan D. Inhibition of alpha 1  adrenergic receptors in the treatment of lower urinary tract dysfunction in multiple sclerosis (1993). Presented at the Irish Neurological Society
  5. O’Riordan JI, Javed M, Murphy R, Hutchinson M. Anticardiolipin antibodies and Sneddon’s syndrome.  (1993) Presented at Irish Neurosciences group meeting
  6. Javed M, O’Riordan JI, Murphy R. Adrenomyeloneuropathy - presenting as schizophrenia like psychosis, Addison’s disease and paraparesis (1993) Presented at Irish Neurosciences group meeting
  7. O'Riordan JI, Kellet J. Retrospective decision analysis of thrombolytic therapy. Ir J Med Sci 1993;162:49          
  8. O'Riordan JI, Javed M, Hutchinson M. The spectrum of nonmalignant sensory polyganglionopathy. Ir J Med Sci 1994:163;S(13):29.
  9. O'Riordan JI, Javed M, Hutchinson M. Limb ataxia, facial numbness, and Adie's pupils; ataxic ganglionopathy. J Neurol Neurosurg Psychiatry 1994; 57:1296. Presented at the Association of British Neurologists
  10. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D.Indoramin for lower urinary tract dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57:1296 Presented at the Association of British Neurologists
  11. Hutchinson M,O'Riordan J,Javed M,MacErlaine D,Willcox T,Parphrey N,Tournier-Lasserve E. Cerebral autosomal dominant arteriopathy and leucoencephalopathy associated with familial hemiplegic migraine. Ann Neurol 1994:36:263. Presented at the American Neurological Association
  12. O'Riordan JI, Gallagher H, Kingsley DPE, Thompson EJ, McDonald WI, Miller DH. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1995;59:217 Presented at the Association of British Neurologists
  13. Hutchinson M, O'Riordan JI, Javed M, Quin E, Willcox T, MacErlaine D, Nagy TG, Tounier-Lasserve E. Familial hemiplegic migraine and the age related spectrum of cerebral autosomal dominant arteriopathy linked to chromosome 19. J Neurol Neurosurg Psychiatry 1995;59:207 Presented at the Association of British Neurologists
  14. O'Riordan JI, Miller DH, Thompson AJ. Devic's neuromyelitis optica: a distinct neurological disorder. Ann Neurol 1995;38:294 Presented at the American Neurological Association
  15. O’Riordan JI, AJ Thompson, DPE Kingsley, DH Miller. Devic’s Neuromyelitis Optica - a century of misunderstanding (1995).
  16. O'Riordan JI, Thompson AJ, McDonald WI, Miller DH. The rationale for inclusion of patients with clinically isolated syndromes in treatment trials for multiple sclerosis (1996). Presented at the Irish Neurological Society
  17. O’Riordan JI, AJ Thompson, DH Miller. Post infectious encephalomyelitis - a long term clinical and MRI follow-up with differentiation from MS (1997) Presented at the Irish Neurological Society
  18. O’Riordan JI, Hirsch N, Howard RS. Crisis in myasthenia gravis: precipitating factors, management and outcome(1998) Presented at the Irish Neurological Society
  19. O'Riordan JI, McDonald WI, Miller DH. The prognostic significance of brain MRI in clinically isolated syndromes suggestive of demyelination : a 10 year follow up. J Neurol Neurosurg Psychiatry 1996; 61:214. Presented at the Association of British Neurologists
  20. O'Riordan JI, Gawne-Caine M, Miller DH. Comparison of fast FLAIR and conventional spin echo for detection of multiple sclerosis lesions in the brain. J Neurol Neurosurg Psychiatry 1996;61:221. Presented at the Association of British Neurologists
  21. O'Riordan JI, Mottershead JM, Hirsch N, Miller DH, Howard RS. Thymectomy for myasthenia gravis: clinical course and outcome. J Neurol Neurosurg Psychiatry 1996; 61:224. Presented at the Association of British Neurologists
  22. Brenner R, O'Riordan JI, Howard RS, Miller DH. Myasthenia gravis, thymoma, and nephrotic syndrome. J Neurol Neurosurg Psychiatry 1996; 61:225. Presented at the Association of British Neurologists
  23. Losseff NA, O'Riordan J, McDonald WI, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible MRI method to monitor disease progression. J Neurol Neurosurg Psychiatry 1996; 61:219. Presented at the Association of British Neurologists
  24. O'Riordan JI, Thompson AJ, Rudge P, McDonald WI, Miller DH. Indications for the use of disease modifing agents in isolated syndromes suggestive of demyelination. Eur J Neurol 1996; (S4) 3:3. Presented at ECTRIMS
  25. O'Riordan JI, Losseff NA, Thompson AJ, McDonald WI, Miller DH. High resolution brain and spinal cord MRI in clinically isolated syndromes. Eur J Neurol 1996; (S4) 3:6  . Presented at ECTRIMS .
  26. O'Riordan JI, Thompson AJ, Rudge P, McDonald WI, Miller DH. The long term risk of multiple sclerosis following clinically isolated syndromes of the central nervous system. J Neurol 1996; (S2) 243:33. Presented at the European  Neurological Society
  27. O'Riordan JI, Losseff N, Thompson AJ, Miller DH. Asymptomatic spinal cord lesions in clinically isolated optic neuritis or brain stem syndromes. J Neurol 1996; (S2) 243: 18. Presented at the European  Neurological Society
  28. O'Riordan JI, Mottershead JP, Hirsch N, Miller DH, Howard RS. The intensive care management of myasthenia gravis. J Neurol 1996;(S2) 243:15. Presented at the European  Neurological Society
  29. Robertson N, O’Riordan J, Chataway J, Kingsley D, Miller D, Compston DAS. Conjugal multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63:696. Presented at the Association of British Neurologists
  1. Gawne-Cain M, O’Riordan JI, Coles A, Newell B, Thompson A, Miller DH. Which sequence for multiple sclerosis (MS) lesion volume measurement in clinical trials? A comparsion of fast Fluid Attenuated Inversion Recovery and spin echo sequences. J Neurol 1997; (S3) 244:38 Presented at the European  Neurological Society
  2. Sailer M, O’Riordan JI, Kingsley DPE, Thompson AJ, McDonald WI, Miller DH. Long term predictive value of quantitative brain MRI in patients presenting with a clinically isolated syndrome suggestive of demyelination. J Neurol 1997; (S3) 244:38. Presented at the European  Neurological Society
  3. O’Riordan JI, Thompson AJ, MacManus DG, Moseley IF, McDonald WI, Miller DH. The long term prognosis of acute disseminated encephalomyelitis. J Neurol 1997; (S3) Presented at the European  Neurological Society 244:10
  1. O’Riordan JI, Gawne-Cain M, Coles A, Compston A, Miller DH. T1 hypointense lesion load assessment in secondary progressive multiple sclerosis. J Neurol 1998; 245: 440 Presented at the European  Neurological Society
  2. O’Riordan JI, Thompson AJ, Rudge P, McDonald WI, Miller DH. The significance of brain abnormalities at presentation with clinically isolated syndromes suggestive of MS - a 10 year follow - up (1996)
  3. O’Riordan JI, Thompson AJ, MacManus DG, Miller DH. Acute disseminated encephalomyelitis - long term MRI and clinical follow-up (1997)
  4. O’Riordan JI, Lossef NA, Phatorus C, Miller DH. Asymptomatic spinal cord lesions in  clinically isolated optic nerve, brain stem and spinal cord syndromes suggestive of demyelination (1997)
  5. Hutchinson S, O’Riordan J, Farrell M, Hutchinson M. Relapsing polyneuropathy and brain stem encephalitis: a clinical and pathological case report. J Neurol Neurosurg Psychiatry 1997; 63: 268 Presented at the Association of British Neurologists
  6. O’Riordan JI, Gawne-Cain M, Coles A, Miller DH. Multiparametric MRI study in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65; 702 - 703. Presented at the Association of British Neurologists
  7. Brex P, O’Riordan JI, Miszkiel KA, Barker GJ, MacManus DG, Moseley IF, McDonald WI, Plant GP, Miller DH. A multi parameter MRI study of clinically isolated syndromes suggestive of multiple sclerosis with 3 month follow-up. J Neurol 1998; 245: 441 Presented at the European  Neurological Society
  8. Bhidayasiri R, O’Riordan J, Howard RS, Sharief MK.  A case of relapsing Bickerstaff’s encephalitis.  J Neurol Neurosurg Psychiatry 2000; 68 :264 Presented at the Association  of British Neurologists
  9. Brex P, Miszkiel KA, O’Riordan JI, Plant GT, Moseley IF, Thompson AJ, Miller DH. Development of new lesions on serial T2-weighted MRI increases the risk of the early development of MS following a clinically isolated syndrome. J Neurol 2000; 247: 20 Presented at the European  Neurological Society
  10. Parratt JDE, Tavensdale R, Parratt D, Swingler R, O’Riordan J. Elevated levels of Chlamydia Pneumonia specific immunoglobulins in a subgroup of patients with multiple sclerosis. J Neurol 2000; 247: 58. Presented at the European  Neurological Society
  11. Brex PA, Miszkiel KA, O’Riordan JI, Moseley IF, Plant GT, Thompson AJ, Miller DH. Quantitative brain MRI in patients presenting with clinically isolated syndromes: results of the new London cohort. J Neurol 2000; 247: 138. Presented at the European  Neurological Society
  12. Dalton CM, Brex PA, Gordon N, Fox N, O’Riordan JI, Plant G, Thompson AJ, Miller DH. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the development of multiple sclerosis. J Neurol 2001; 248: 26. Presented at the European  Neurological Society
  13. Brex PA, O’Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH.  Repeat brain imaging improves prognostic value of MRI in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71; 423 Presented         at the Association of British Neurologists
  14. Parratt J, Tavendale R, Parratt D, Swingler R, O’Riordan J. Does Chlamydia pneumoniae infection occur in multiple sclerosis? A preliminary investigation of cerebrospinal fluid. J Neurol Neurosurg Psychiatry 2001; 71; 423 Presented at the Association of British Neurologists
  15. Parratt JDE, Wilson S, Donnan P, O’Riordan J, Swingler R. Clustering of  multiple sclerosis cases in Tayside and their relation with deprivation and population density. J Neurol Neurosurg Psychiatry 2001; 71: 423 Presented at the Association of British Neurologists
  16. Parratt J, Lindsay P, Wilson S, O'Riordan J. The relationship between deprivation and multiple sclerosis in Tayside, Scotland. J Neurol Sci 2001: 187: S336 Presented at the World Congress of  Neurology
  17. Dalton CM, Brex PA, O'Riordan JI, Miller DH. Diagnosis of multiple sclerosis in patients with clinically isolated syndromes using the new (McDonald) criteria at three months. Multiple sclerosis 2001; 7: S1 Presented at ECTRIMS
  18. Wilson S, Parratt J, O'Riordan J, Swingler R. Premenstrual worsening of MS symptoms. J Neurol Sciences 2001: 187: S336 Presented at the World Congress of  Neurology
  19. Parratt J, Travendale R, Parratt D, Swingler R, O'Riordan J. Active systemic Chlamydia Pneumoniae infection in patients with multiple sclerosis. J Neurol Sciences 2001: 187: S344. Presented at the World Congress of  Neurology
  20. Relationship between serial MRI and the development of disability in patients with clinically isolated syndromes suggestive of multiple sclerosis. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. J Neurol Neurosurg Psychiatry 2001; 71:423 Presented at the Association of British Neurologists
  21. O’Riordan JI. Painful Horner’s syndrome and disection of the internal carotid artery (1998). Presented at the IRISH NEUROSCIENCES GROUP MEETING
  22. O’Riordan JI, McDonald WI, Miller DH. The predictive value of MRI in clinically isolated syndromes suggestive of demyelination (1996) Presented at the MULTIPLE SCLEROSIS SOCIETY RESEARCH GRANT HOLDERS MEETING (LONDON)
  23. O’Riordan JI. Chlamydia pneumoniae as a co-factor in the development of MS (2000 Presented at the SCOTTISH MULTIPLE SCLEROSIS SYMPOSIUM – ST ANDREWS
  24. O'Riordan JI. MRI in clinically isolated syndromes of the central nervous system (2001) Presented at the SCOTTISH MULTIPLE SCLEROSIS SYMPOSIUM – ST ANDREWS
  25. Wilson S, Donnan P, Swingler R, O'Riordan J. A serial observation study on hormonal  influences in MS symptoms. Multiple Sclerosis 2004; 10, S2, 188-189 Presented at ECTRIMS
  26. O’Riordan JI.  Natural history of demyelinating lesions - role of kindling. Presented at the Demyelinating disease seminar, Dublin 2004
  27. O'Riordan JI. Inflammatory/demyelinating disorders other than MS - Devic's NMO & ADEM NEUROIMMUNOLOGY CONFERENCE (2005) Visiting Professor, The Sahlgrenska Acadamey at Goteborg University, Sweden
  28. Shah P, O’Riordan JI. Role of dietary intervention in early relapsing remitting MS (2006) Presented at the SCOTTISH ASSOCIATION OF NEUROLOGICAL SCIENCES
  29. Shah P, Wilson S, O’Riordan JI. Hormonal effects on MS Symptoms in women (2006) Presented at the SCOTTISH ASSOCIATION OF NEUROLOGICAL SCIENCES
  30. Shah P, Wilson S, O’Riordan JI The Role of Diet in Early Relapsing Remitting MS: A comparison of the two currently recommended dietary interventions (The Best Bet Diet and the diet advised by the MS Society) on disease activity – A Randomised Controlled Single Blind Pilot Study. (Ongoing clinical trial) Presented at the European Federation of Neurological Sciences 2007
  31. Shah P, Wilson S, O’Riordan JI Prevalence of gut permeability in MS and evaluation of gut permeability with Best Bet Diet in MS – A controlled Pilot Study. (Ongoing clinical trial) Presented at the European Federation of Neurological Sciences 2007
  32. PS Shah, S Gandy, JG Houston, JI O’Riordan. A comparison of MP-RAGE and 3D-FLASH (SPGR) MRI sequences for measurement of brain volume in relapsing remitting MS Presented at the European Federation of Neurological Sciences 2007
  33. Shah P, O’Riordan JI Occult pleomorphic sarcoma presenting as a complex paraneoplastic movement disorder. IAN/ ABN joint conference 2007
  34. Shah P, O’Riordan JI Vitamin D levels in Patients with Multiple Sclerosis IAN/ ABN joint conference 2007
  35. Shah P, O’Riordan JI. Time of Birth and Risk of MS. IAN/ ABN joint conference 2007
  36. O’Riordan JI. What MRI tells us about prognosis and future disability. PRACTICAL ISSUES IN MS MANAGEMENT MEETING – Dublin (2001)
  37. O’Riordan JI. Disese modifying therapy in multiple sclerosis. MANAGING DISABLING NEUROLOGICAL DISORDERS  - EDINBURGH (2001)
  38. O'Riordan JI Neutralising antibodies have clinical implications in disease modifying therapy in MS. Biogen Academy Debate - Edinburgh 2005
  39. P Shah, L Gold, JI O’Riordan. Clinical and MRI analysis of dietary intervention in early  relapsing remitting MS. Multiple Sclerosis 2008 Presented at ECTRIMS
  40. Sammler E, O’Riordan JI,   Swingler R, Poole J, Hormuzudi S. Phenotype and genotype of a patient with McLeod syndrome. J Neurol Neurosurg Psychiatry 2008; Presented at the Association of British Neurologists
  41. O’Riordan JI. Clinicopathological conference. Case discussion 2008.  Presented at the Association of British Neurologists
  42. O’Riordan JI. Current treatment paradigms in multiple sclerosis. MS Trust Annual Conference, Stirling 2009
  43. O’Riordan JI. Sharing the experience: regulatory overview and real life experience in the UK. The Changing Face of MS, Glasgow 2011
  44. O’Riordan JI. Overview of Multiple Sclerosis – current and future treatments. Angus CHP protected learning event 2011
  45.                                                                                                     

  46. Parratt J, Swingler R, O’Riordan J. Increasing age at onset of multiple sclerosis. Multiple Sclerosis 2011; 17: S277- S505. Presented at the 5th joint triennial ECTRIMS/ACTRIMS
  47. McDougall, Roberts R, Adbelaziz, Swingler R, O’Riordan J. Personality change and behavioural disturbance in a 33 year old woman. Presented at the SCOTTISH ASSOCIATION OF NEUROLOGICAL SCIENCES 2011. Won prise for best overall presentation
  48. Waddell B, Grieve K,Walker P, O’Riordan J Gabapentin for spasticity in multiple sclerosis – lack of efficacy data using the Wartenburg’s pendulum test. Multiple Sclerosis 2012 Presented at ECTRIMS
  49. Rog D,O’Riordan J, Mottershead JP. A two year observational study of patients with relapsing remitting multiple sclerosis to assess the outcome of switching between disease modifying therapy in routine UK clinical practice. Multiple Sclerosis 2012 Presented at ECTRIMS
  50. Grieve K, Waddell B, Walker P, O’Riordan J. Cancer and disease modifying therapy in multiple sclerosis: an audit of the Tayside DMT register. Multiple Sclerosis 2012 Presented at ECTRIMS